3 years ago

iLoF Secures $5 Million to Accelerate Personalized Drug Discovery

  • iLoF, a digital health company based in Oxford, UK and Porto, Portugal, has raised $5 million in Series A funding

  • The round was led by Faber, with participation from M12, Quiet Capital, Lunar Ventures, Alter Venture Partners, re.Mind Capital, and Fluxunit

  • Angel investor Charlie Songhurst and Berggruen Holdings also participated

  • iLoF is using the funds to accelerate engagements with global corporations in the pharmaceutical, biotech, and clinical space

  • They are building an AI-platform to accelerate personalized drug discovery and development by collecting massive amounts of data to build a digital library of biomarkers and biological profiles.

      • ProblemHealthcare

      "Recruiting patients for clinical trials is a time-consuming and expensive process, delaying the development of new treatments."

      Solution

      "iLoF uses AI and Photonics to build a digital library of biomarkers and biological profiles, which helps accelerate patient recruitment for clinical trials."

      Covered on